Novartis' drug pricing, information causing friction

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.377, 2002-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novartis advises of updated prescribing information for Exjade

Inpharma, Vol. 1, Iss. 1589, 2007-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

Global over-the-counter (OTC) drug sales for Novartis rose 5% in 2001

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 350, 2002-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Global drug pricing news

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 347, 2002-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Reference drug-pricing systems in Europe

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 320, 2001-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

The allergic asthma drug omalizumab [`Xolair'; Genentech/Novartis] is expected to cost an average $US10 000 annually when it is launched

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 418, 2003-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite